Company Overview
| Stock Name | Sipai Health |
|---|---|
| Stock Code | 00314 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 經營特藥藥房業務、醫生研究協助及健康保險服務。特藥藥房業務為中國最大私營特藥藥房;醫生研究協助為最大腫瘤現場管理組織(SMO);健康保險服務透過健康服務提供商網絡服務大量會員。 |
| Listing Date | 2022-12-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 廣東省廣州市廣州國際生物島螺旋大道51號官洲生命科學創新中心A塔26樓11–13室 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.medbankshealthtech.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 18.60 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2022-12-12 to 2022-12-15 |
| Global Offering Shares | 9,919,400 shares |
| HK Public Offer Shares (Initial) | 992,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 8,927,400 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 763,025,314 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 184,500,840 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.26B |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +670% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 14,192,270,840 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損約人民幣3,748.5百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 64,100,840 |
| Listing Expenses / Funds Raised | ~34.74% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue | 1,039,011 | 2,699,647 | 3,473,930 |
| Cost of sales | -957,207 | -2,512,787 | -3,190,481 |
| Gross profit | 81,804 | 186,860 | 283,449 |
| Other income and gains, net | 7,004 | 34,808 | 51,069 |
| Selling and distribution expenses | -116,032 | -183,450 | -291,461 |
| Administrative expenses | -219,462 | -361,242 | -670,021 |
| Operating profit | -273,637 | -379,914 | -695,699 |
| Net finance costs | -2,877 | -3,527 | -3,688 |
| Share of associates and JVs | 586 | -65 | 137 |
| Profit before tax | -596,020 | -1,040,850 | -3,747,678 |
| Income tax expense | -38 | -51 | -1,179 |
| Profit for the year | -596,071 | -1,042,029 | -3,748,503 |
| Profit attributable to owners | -594,595 | -1,042,781 | -3,740,455 |
Balance Sheet
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Cash and cash equivalents | 199,110 | 1,628,021 | 535,849 |
| Trade and bills receivables | 38,717 | 44,602 | 171,195 |
| Inventories | 211,186 | 279,931 | 269,035 |
| Total current assets | 958,653 | 2,292,156 | 2,488,243 |
| Total assets | 1,151,106 | 2,478,598 | 2,892,819 |
| Total current liabilities | 337,419 | 613,245 | 830,800 |
| Total liabilities | 2,158,043 | 4,270,245 | 8,323,729 |
| Total equity | -1,006,937 | -1,791,647 | -5,430,910 |
| Equity attributable to owners | -1,010,590 | -1,796,652 | -5,429,224 |
Income Statement
Balance Sheet
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 25.0 |
|---|---|
| First Day Open | HK$ 23.7 |
| First Day Change | 34.41% |
| First Day Volume | 2174600.0 |
| First Day Turnover | 52611300.0 |
| Use of Proceeds | 1、約87%或約104.8百萬港元預計將用于業務擴張;
2、約13%或約15.6百萬港元預期將用于技術研發及提升技術基礎設施。 |
Underwriting Syndicate
Joint Lead Managers (5)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 馬旭廣 | — |
| Company Secretary | 任娜、曾穎雯 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 馬旭廣先生及李繼先生(一致行動人)合計持有約21.43%股權;騰訊集團持有約27.41%股權。 |
|---|




